Bli medlem
Bli medlem

Du är här


ExpreS2ion Biotechnologies: ExpreS2ion and ABIVAX announce development collaboration on the Ebola prophylaxis and treatment program, ABX544

Horsholm, Denmark and Paris, France, December 12, 2016 - Today,
ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a fully owned
subsidiary of ExpreS2ion Biotech Holding AB, and ABIVAX S.A.,
(Euronext Paris: FR0012333284 - ABVX), an innovative biotechnology
company targeting the immune system to eliminate viral disease, have
entered into a service agreement and a term sheet for a commercial
license agreement under which ExpreS2ion and ABIVAX collaborate in
the development of their proprietary prophylactic and treatment for
Ebola virus infection, ABX544. The financial terms of the agreement
were not disclosed.

The Agreement

ExpreS2ion and ABIVAX have signed a Process Development Service
Agreement ("the Service Agreement"), as well as a term sheet for a
Commercial ExpreS2ion Platform License Agreement ("the License
Agreement") for ABX544, which specifies the terms and conditions for
a commercial license to ExpreS2ion's proprietary technology platform,
ExpreS2. According to the Service Agreement, ExpreS2ion will develop
a process for the GMP production of an Ebola antigen, which is
required for the production of ABX544. The overall preclinical work
package is expected to be executed in 2017. The corresponding License
Agreement is scheduled to be signed within three months. The
financial terms of the agreement were not disclosed.


Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever,
is a severe and often fatal illness in humans. The virus is
transmitted to humans from wild animals (fruit bats and monkeys) and
following spread in the human population through human-to-human
transmission. The average EVD case fatality rate is around 50%, but
fatality rates have varied from 25% to 90% in past outbreaks. The
first EVD outbreaks occurred in remote villages in Central Africa
near tropical rainforests, but the most recent outbreak in West
Africa has involved major urban as well as rural areas. This 2014/15
outbreak was particularly severe, causing the disease in >28.000
individuals of which >11.000 died. There are currently no licensed
Ebola vaccines (but two potential candidates are undergoing
evaluation) and no specific treatments (WHO Jan. 2016).


The ABX544 program targets the generation of an Ebola hyperimmune
anti-serum, containing neutralising antibodies produced from animals
immunised with a specific Ebola antigen. In contrast to a vaccine
that needs time to generate a protective response, ABX544 should have
an immediate effect when administered. It can be applied either as
treatment of infected persons or for protection of non-infected
persons including health care workers, constituting a first line of
defence during epidemic outbreaks. Following the formal preclinical
evaluation including toxicology, ABIVAX aims to bring ABX544 into
clinical trials.

Executive Management Comments

Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX, said: "We are pleased to
have entered into this agreement with ExpreS2ion, as this will be a
major enabler for our ABX544 Ebola program. Ebola is a devastating
disease with no licensed vaccines or therapeutics, and ABX544 has the
potential to address the urgent need for immediate prophylaxis and
treatment during future outbreaks."

Dr. Steen Klysner, CEO, ExpreS2ion, commented: "We are pleased that
ABIVAX has chosen our ExpreS2 platform to produce the antigen
required for their ABX544 Ebola programme. We see a good synergy
between the ExpreS2 platform's capability for rapid production of
high quality antigens and ABIVAX' approach for ABX544 and we look
forward to support the development of this first-in-class product."

About Abivax

ABIVAX (Euronext Paris: FR0012333284 - ABVX) is an innovative
biotechnology company focused on targeting the immune system to
eliminate viral disease. ABIVAX leverages three technology platforms
for drug discovery: an anti-viral, an immune enhancement, and a
polyclonal antibody platform. ABX464, its most advanced compound, is
currently in Phase II clinical trials for providing a functional cure
for patients with HIV/AIDS. It is a first-in-class oral small
anti-viral molecule which blocks HIV replication through a unique
mechanism of action and also has a strong anti-inflammatory effect.
In addition, ABIVAX is advancing a clinical stage immune enhancer as
well as multiple preclinical candidates against additional viral
targets (i.e. Chikungunya, Ebola, Dengue) and several of these
compounds are planned to enter clinical development within the next
18 months.

Contacts ExpreS2ion

For further information, please contact:

Dr. Steen Klysner, CEO ExpreS2ion Biotechnologies
Telephone: +45 2062 9908

Certified Advisor

Sedermera Fondkommission is appointed as Certified Adviser for

Contacts ABIVAX

Alain Chevallier

+33 1 53 83 08 41

ABIVAX Press Relations


Caroline Carmagnol/Margaux Pronost

+33 6 64 18 99 59 / +33 1 44 54 36 65

MC Services

Anne Hennecke/Solveigh Maehler

+49 211 529 252 19

LifeSci Advisors

Chris Maggos

+41 79 367 6254

For further information, please contact

Dr. Steen Klysner, CEO ExpreS2ion Biotechnologies
Telephone: +45 2062 9908

This press release is information that ExpreS2ion is obliged to make
public pursuant to the EU Market Abuse Regulation. The information
was submitted for publication, through the agency of the contact
person set out above on December 12, 2016.

About ExpreS2ion

ExpreS2ion Biotech Holding AB (Nasdaq First North: EXPRS2; CR No.
559033-3729), has through the wholly owned Danish subsidiary
ExpreS2ion Biotechnologies ApS, developed a platform technology
enabling cost effective and robust production of complex proteins for
the development of vaccines and diagnostics for e.g. Malaria and
Zika. Since foundation in 2010, the subsidiary has used its patented
ExpreS2platform to produce more than 200 proteins in collaboration
with research institutions and biopharmaceutical companies, with an
efficiency and success rate superior to competing technologies.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.